fbpx

Telix Pharmaceuticals

24/9 update: Gozellix has received US CMS transitional pass-through (TPT) status, effective from 1 Oct-25.
Transitional pass through (TPT) status allows for a separate payment in addition to payment for imaging in the outpatient setting.

22/9 update: Buy with a stop-loss at $14.10

You're not a member!  Trial today

Telix Pharmaceuticals

Leave a Reply

Investor Signals Pty Ltd ABN 44 143 555 453 is a Corporate Authorised Representative CAR No. 439411 of Advisor Plus Pty Ltd AFSL 474520
© 2025 Investor Signals

Send our ASX Research to your Inbox

Or start a free thirty day trial for our full service, which includes our ASX Research.